LM-302 + nivolumab

LM-302 + nivolumab is a combination therapy consisting of LM-302, an antibody-drug conjugate (ADC) targeting Claudin 18.2 (CLDN18.2), and nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor. **LM-302** is a recombinant humanized IgG1 monoclonal antibody against CLDN18.2, conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE), enabling targeted cytotoxic delivery to CLDN18.2-positive tumor cells, mainly in advanced/metastatic gastric and gastroesophageal junction (GEJ) adenocarcinomas. **Nivolumab** is an immune checkpoint inhibitor that blocks PD-1, reactivating T-cell mediated antitumor responses. The combination is under investigation in clinical trials for patients with advanced or metastatic CLDN18.2-positive gastric/GEJ cancers, aiming to synergize targeted cytotoxicity (LM-302) with immune checkpoint inhibition (nivolumab)[1][2][3].

Brand names

Opdivo

Other names

LM-302 plus nivolumabLM302 plus nivolumabLM 302 plus nivolumabanti-CLDN18.2 ADC plus nivolumabanti-CLDN-18.2 ADC plus nivolumabanti-CLDN 18.2 ADC plus nivolumab